Processa Pharmaceuticals
Filed with the SEC on · accession 0001493152-26-038334
PCSA filed a 10-Q (quarterly report) with the SEC on Aug 14, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -2.8% by the first close after the filing.
Processa Pharmaceuticals filed its Q2 2026 Form 10-Q, reporting routine quarterly financial results and disclosing subsequent events including a merger agreement with Vidya Therapeutics and a securities purchase agreement involving Series A Preferred Stock.
Close before
$2.50
Aug 13, 2026
First close after
-2.80%
$2.43
5 trading days
-14.20%
$2.15
Since filing
-24.00%
$1.90
✦ Ask GOAX AI about this filing — what it means for PCSA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PCSA?
Click herePCSA filed a 10-Q (SEC filing). Processa Pharmaceuticals filed its Q2 2026 Form 10-Q, reporting routine quarterly financial results and disclosing subsequent events including a merger agreement with Vidya Therapeutics and a securities purchase agreement involving Series A Preferred Stock.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
PCSA closed at $2.50 before the filing and $2.43 on Aug 14, 2026 (-2.80%). Five trading days later: $2.15 (-14.20%).
Get alerts when PCSA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days